[A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].

@article{Jiang2015APM,
  title={[A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].},
  author={Qian Jiang and Donglu Zhao and Jie Jin and Depei Wu and Fanyi Meng and Jianda Hu and Bingcheng Liu and Xin Du and Ting Liu and Yan Li and Ming Xin Hou and Xiaopin Han and Zhixiang Shen and Jun Ma},
  journal={Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi},
  year={2015},
  volume={36 8},
  pages={
          651-5
        }
}
OBJECTIVE To evaluate the early hematologic, cytogenetic and molecular responses in newly diagnosed patients with chronic myelogenous leukemia in chronic phase(CML-CP)and initially treated with a generic imatinib(Xinwei), manufactured by Jiansu Hansoh Pharmaceutical Group Co., Ltd. METHODS 107 newly diagnosed patients of CML-CP, whose ages were above 18- year- old and who had never received any tyrosine kinase inhibitor(TKI)were treated with Xinwei 400 mg QD. The hematologic, cytogenetic and… CONTINUE READING
BETA